[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-nonsmall-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-nonsmall-cell":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,76,98,121,152,178,201,225,252,276],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100548862","phase-2-ctdna-mrd-guided-consolidation-toripalimab-in-stage-ib-iiia-nsclc-100548862",false,"NCT06426511","ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC","Consolidation Toripalimab Therapy Guided by Circulating Tumor DNA (ctDNA)-Minimal Residual Disease (MRD) for Completely Resected Stage IB-IIIA Non-small-cell Lung Cancer (Without EGFR or ALK Alterations for Nonsquamous Lung Cancer)","CONTINUE","Inclusion Criteria:\n\n* Subjects must have undergone complete surgical resection (R0) of their stage IB , II and select IIIA NSCLC according to the AJCC 8th edition staging;\n* Squamous or non-squamous NSCLC histology;\n* Subjects should be without EGFR or ALK alterations for nonsquamous NSCLC;\n* Male and female, aged 18-75 years;\n* Surgery for lung cancer must be completed ≤ 60 days prior to study treatment;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n* Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109\u002FL, and Platelet count ≥100 x 109\u002FL, and Hemoglobin ≥9 g\u002FdL (may be transfused to maintain or exceed this level);\n* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN;\n* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml\u002Fmin;\n* Female subjects should not be pregnant or breast-feeding;\n* Written informed consent provided. Being willing and able to comply with the visits, treatment plan, laboratory examinations and other study procedures scheduled in the study.\n\nExclusion Criteria:\n\n* Not R0 resection, or metastatic disease.\n* Subjects with known EGFR sensitive mutations or ALK translocation, EGFR and ALK mutation status needs to be identified for the subjects with non-squamous NSCLC;\n* Previous treatment with systemic antitumor therapy for NSCLC;\n* Severe allergic reaction to other monoclonal antibodies;\n* Subjects with any known or suspected autoimmune disorder or immunodeficiency, with the following exceptions: hypothyroidism, hormone therapy is not needed, or well controlled at physiological dose; controlled type I diabetes;\n* Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen in screening period with HBV-DNA detected higher than the upper limit of normal at the clinical laboratory of the study center); active hepatitis C (defined as positive hepatitis C surface antibody in screening period and positive HCV-RNA);\n* Vaccination of live vaccine within 30 days prior to the first dose;\n* Evidence of clinically active interstitial lung disease;\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);\n* Inability to comply with protocol or study procedures;\n* Any unstable systemic disease (including active infection, active tuberculosis uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease);\n* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study and may confuse the study results;\n* History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.\n* Women who are pregnant or nursing.\n* Ingredients mixed with small cell lung cancer patients.","ALL","18 Years","75 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after adjuvant therapy. Toripalimab is a humanized monoclonal antibody for human programmed cell death protein 1. Toripalimab was approved as a consolidation treatment after perioperative therapy in combination with chemotherapy for resectable stage III NSCLC.",[28],"Lung Cancer, Nonsmall Cell","RECRUITING","2026-04-19",{"date":32,"type":33},"2026-04-23","ACTUAL",{"date":35,"type":33},"2024-12-01",{"date":37,"type":22},"2029-12-01",{"name":39,"class":40},"Sun Yat-sen University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":63,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100592655","prospective-data-collection-initiative-on-thoracic-malignancies-100592655","NCT06996249","Prospective Data Collection Initiative on Thoracic Malignancies","Prospective Data Collection Initiative on Thoracic Malignancies - a Prospective Observational Cohort Study","DuTOC","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Histo\u002Fcytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board);\n* Informed consent for longitudinal observational data collection;\n\nExclusion Criteria:\n\n* Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator.\n* Inability to provide a written or electronic informed consent.",{"count":51,"type":22},12000,"50 Years","OBSERVATIONAL","Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of molecular factors, biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage. It is however still unclear which, how, and to what extent these factors will influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) thoracic malignancies such as lung cancer.\n\nAlthough the results from prospective clinical trials will remain the backbone of evidence-based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of patients with cancer do not participate in clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications:\n\n1. It is highly desirable to validate the results from clinical trials in the general patient population. This is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters.\n2. There is an ever increasing number of therapeutic interventions available for which its efficacy depends on known and unknown tumor-specific, clinical, demographic and other patient characteristics. Large numbers of patients are required to test the relevance of these variables.\n3. As a result of rapid technical and drug developments, new minimally invasive treatment options such as stereotactic irradiation or ablation techniques or sublobar resections and new targeted and immunotherapeutic treatments have entered the clinic. These interventions have potentially less side effects compared to the conventional treatments. Still, these new interventions will have to prove their effectiveness, safety and superiority (or non-inferiority) in a real world setting.\n4. Many hypotheses related to further optimization of personalized medicine can currently not be tested as they require a large prospective cohort of patients, and a less time-consuming and costly research infrastructure.\n\nA prospective observational cohort study has the potential to fill the gap between prospective randomized trials (efficacy) and patients treated in general practice (effectiveness) and it will enable accrual of clinical trials (innovation).",[56,57,28,58,59,60,61,62],"Lung Cancer","Thoracic Cancer","Adenocarcinoma","Squamous Cell Carcinoma","Large Cell Lung Cancer","Thymus Cancer","Mesothelioma",[64,65],"Dutch lung cancer cohort","lung cancer cohort","2026-03-02",{"date":68,"type":33},"2026-03-03",{"date":70,"type":33},"2025-08-15",{"date":72,"type":22},"2030-01-01",{"name":74,"class":40},"Dutch Society of Physicians for Pulmonology and Tuberculosis",10,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100415606","phase-1-tocilizumab-and-atezolizumab-in-adults-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-refractory-to-1st-line-immune-checkpoint-inhibitor-based-therapy-100415606","NCT04691817","Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to at least 1 line of therapy\n* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial\n* ECOG PS 0-2\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy\n* Other active invasive malignancy requiring ongoing therapy\n* Evidence of progressing or untreated brain metastases\n* Evidence or history of leptomeningeal disease\n* Uncontrolled tumor related pain\n* History of an autoimmune disease or IPF",{"count":84,"type":22},28,[86,25],"PHASE1","This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.",[28],"2026-01-06",{"date":91,"type":33},"2026-01-07",{"date":93,"type":33},"2023-07-25",{"date":95,"type":22},"2027-09",{"name":97,"class":40},"Abramson Cancer Center at Penn Medicine",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100468829","immunonutrition-for-improving-the-efficacy-of-immunotherapy-in-patients-with-metastatic-non-small-cell-lung-cancer-100468829","NCT05384873","Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer","Multicentre, Randomised, Open-label, Parallel-group Trial to Evaluate Immunonutrition in Improving Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer, Undergoing Systematic Nutritional Counseling","MURAL","Inclusion Criteria:\n\n* Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology);\n* First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines;\n* Will to participate by providing written informed consent;\n* Availability to administer oral supplements and immunotherapy with or without chemotherapy;\n* Eastern Cooperative Oncology Group Performance Status ≤ 2;\n* Life expectancy ≥ 6 months.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Inability to sign an informed consent;\n* Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements",{"count":107,"type":22},180,[109],"NA","The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling",[28],"2025-04-29",{"date":114,"type":33},"2025-05-01",{"date":116,"type":33},"2023-06-01",{"date":118,"type":22},"2027-07-31",{"name":120,"class":40},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":41},"100401659","a-multicenter-cancer-biospecimen-collection-study-100401659","NCT04510129","A Multicenter Cancer Biospecimen Collection Study","Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies","Inclusion Criteria:\n\n1. Subject must have a disease of interest. Specifically, subject must have one of:\n\n   1. head and neck squamous cell carcinoma (HNSCC)\n   2. non-small-cell lung cancer (NSCLC)\n   3. small cell lung cancer (SCLC)\n   4. urothelial carcinoma (UCC)\n   5. gastric or gastroesophageal junction adenocarcinoma\n   6. cervical cancer\n   7. esophageal squamous cell carcinoma (ESCC)\n   8. triple-negative breast cancer (TNBC)\n   9. hepatocellular carcinoma (HCC)\n   10. renal cell carcinoma (RCC)\n   11. colorectal cancer (CRC)\n2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1\u002FPD-L1 immunotherapy for treatment of their cancer.\n3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1\u002FPD-L1 immunotherapy.\n4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1\u002FPD-L1 immunotherapy.\n5. Willing to provide electronic informed consent per IRB-approved protocol.\n6. Able to speak, read, and comprehend English fluently.\n7. Subject is 18 years of age or older.\n8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Subject who does\u002Fdid not have one of the cancers listed above (other histologies).\n3. Subject has already participated in this trial.",{"count":129,"type":22},1650,"This study will collect de-identified tumor samples, with correlated clinical\u002Fdemographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.",[132,28,133,134,135,136,137,138,139,140,141],"Cancer of Head and Neck","Small-cell Lung Cancer","Urothelial Carcinoma","Gastroesophageal Junction Adenocarcinoma","Cervical Cancer","Esophageal Squamous Cell Carcinoma","Triple Negative Breast Cancer","Hepatocellular Carcinoma","Renal Cell Carcinoma","Colorectal Cancer","2025-03-10",{"date":144,"type":33},"2025-03-12",{"date":146,"type":33},"2020-02-05",{"date":148,"type":22},"2027-02",{"name":150,"class":151},"Cofactor Genomics, Inc.","INDUSTRY",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":41},"100567358","phase-2-efficacy-analysis-of-neoadjuvant-treatment-in-lung-cancer-using-low-dose-nivolumab-combined-with-chemotherapy-100567358","NCT06667154","Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy","Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-Dose Nivolumab Combined With Chemotherapy","Inclusion Criteria:\n\n* Able to provide a signed Informed Consent Form (ICF), indicating agreement to comply with the requirements and restrictions in the ICF and protocol.\n* Male or female, aged 18 years or older.\n* Diagnosed with non-small cell lung cancer (NSCLC) with clinical staging IB, II, or IIIA.\n* Receiving treatment at Hospital de Base.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment, with no decline from two weeks prior to the baseline period or the day of the first dose.\n* Tumor sample meets the following requirements:\n* Negative for EGFR gene expression.\n* Negative for ALK and ROS1 protein expression.\n* PD-L1 protein expression documented and assessable.\n* Tumor is considered resectable upon initial assessment by three thoracic oncology surgeons (IR, CM, and HN) following a multidisciplinary review.\n* Adequate organ and bone marrow function as defined below:\n* Hemoglobin: ≥ 9.0 g\u002FdL\\*\n* Absolute neutrophil count: ≥ 1.5 × 10\\^9 \u002FL\\*\n* Platelet count: ≥ 100 × 10\\^9 \u002FL\\*\n* \\*Note: Granulocyte colony-stimulating factor (G-CSF), platelet transfusions, and blood transfusions are not permitted to meet these values.\n* Serum bilirubin: ≤ 1.5 × upper limit of normal (ULN), except for participants with confirmed Gilbert syndrome, who may be included upon physician consultation.\n* ALT and AST: ≤ 2.5 × ULN.\n* Creatinine clearance: ≥ 50 mL\u002Fmin (calculated using the Cockcroft and Gault formula).\n* Life expectancy greater than six months prior to randomization.\n\nExclusion Criteria:\n\n* Refusal to sign the Informed Consent Form (ICF).\n* NSCLC clinical stages IA, IIIB N3, IIIC, IVA, and IVB.\n* Tumors with T4 invasion of the aorta, esophagus, and\u002For heart; or presence of bulky N2 disease.\n* Tumor deemed unresectable.\n* Prior systemic anticancer therapy for NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational drugs.\n* History of another primary malignancy, with exceptions for:\n* Malignancies treated with curative intent and no active disease for ≥ 2 years before the first dose of investigational product (IP) and with a low risk of recurrence.\n* Adequately treated non-melanoma skin cancer or lentigo maligna with no evidence of disease.\n* Adequately treated carcinoma in situ with no evidence of disease.\n* Incomplete basic medical information in the electronic medical record.\n* Positive for EGFR gene expression.\n* Positive for ALK protein expression.\n* No available data on PD-L1 protein expression.\n* Positive for ROS1 protein expression.\n* Pregnant or breastfeeding at the time of enrollment.",{"count":160,"type":22},33,[25],"The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.",[28,164],"Non-Small Cell Lung Cancer NSCLC",[166,167,168],"Low Dose Immunotherapy","Neoadjuvant immunotherapy","Non-Small-Cell-Lung-Cancer","2024-10-29",{"date":171,"type":33},"2024-10-31",{"date":173,"type":33},"2023-10-10",{"date":175,"type":22},"2027-10-31",{"name":177,"class":40},"Aline Fusco Fares, MD",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":41},"100409467","study-of-pro-in-patients-with-advanced-pancreatic-or-biliary-tract-cancer-bettereveryday-100409467","NCT04611867","Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)","Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or BiliaryTract Cancer (BetterEveryDay)","BetterEveryDay","Inclusion Criteria:\n\n* Adult (aged 18 and over)\n* Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer\n* Written informed consent before any study procedures\n* Planning to receive 1st line systemic anticancer therapy within ≤2 weeks\n* Performance status: ECOG 0-2\n* Access to the internet\n* Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member\n\nExclusion Criteria:\n\n* No mobile device\n* Exhibiting signs of overt psychopathology or cognitive dysfunction\n* Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments\n* Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.",{"count":187,"type":22},274,[109],"Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with pancreatic and lung cancer have highest rates of unplanned hospitalizations. Investigator initiated prospective \"Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)\" is to be initiated based on the great need for optimizing treatment care, reducing hospitalizations and improving outcomes.",[191,28],"Pancreatic Cancer","2024-09-30",{"date":194,"type":33},"2024-10-02",{"date":196,"type":33},"2021-08-17",{"date":198,"type":22},"2027-04-01",{"name":200,"class":40},"Inna Chen, MD",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100556869","phase-2-a-study-to-evaluate-the-efficacy-of-osimertinib-in-patients-with-egfr-sensitive-mutated-non-small-cell-lung-cancer-progression-after-receiving-adjuvant-targeted-therapy-following-radical-surgery-100556869","NCT06530719","A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery","A Prospective, Single-arm, Single-center, Phase II Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery","Inclusion Criteria:\n\n1. Aged 18 years or older (inclusive).\n2. Histologically confirmed NSCLC (according to the 8th edition of AJCC lung cancer staging standards).\n3. Subjects must be patients with stage IB-IIIB NSCLC after previous radical surgery, who received adjuvant targeted therapy with EGFR TKIs (first-, second-, or third-generation EGFR TKIs) after surgery, and had tumor recurrence and progression more than 3 months after the end of the adjuvant therapy course.\n4. Tumor tissue samples or blood samples previously diagnosed with NSCLC were confirmed to have EGFR sensitive mutations by qualified laboratory tests.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 and no deterioration in the previous 2 weeks, with a minimum expected survival of 12 weeks.\n6. Patients must have at least 1 tumor lesion that can be accurately measured at baseline, with the longest diameter ≥10 mm at baseline (if it is a lymph node, the short diameter must be ≥15 mm). The selected measurement method is suitable for accurate repeated measurements, which can be computed tomography (CT) or magnetic resonance imaging (MRI). If there is only one measurable lesion, it can be accepted as a target lesion, and a baseline evaluation of the tumor lesion must be performed at least 14 days after the diagnostic biopsy.\n7. Within 7 days before treatment, the international normalized ratio (INR) is ≤1.5, or the prothrombin time (PTT) and activated partial thromboplastin time (aPTT) are ≤1.5×ULN.\n8. Women of childbearing age should take appropriate contraceptive measures from screening to 6 months after stopping study treatment and should not breastfeed. Before starting medication, the pregnancy test is negative, or one of the following criteria is met to prove that there is no risk of pregnancy:\n\n   1. Postmenopause is defined as age greater than 50 years and amenorrhea for at least 12 months after stopping all exogenous hormone replacement therapy;\n   2. Women under the age of 50 can also be considered postmenopausal if they have amenorrhea for 12 months or more after stopping all exogenous hormone therapy and their luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels are within the laboratory postmenopausal reference range;\n   3. Those who have undergone irreversible sterilization surgery, including hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but excluding bilateral tubal ligation.\n9. Male patients should use barrier contraception (i.e. condoms) from screening to 6 months after stopping study treatment.\n10. The subjects themselves voluntarily participate and sign the informed consent in writing.\n\nExclusion Criteria:\n\n1. Patients who have received any of the following anti-tumor treatments:\n\n   a) Patients who have received platinum-containing chemotherapy or other chemotherapy after disease progression; b) Patients who have received other EGFR TKI targeted therapy after disease progression; c) Patients who have received chest radiotherapy after disease progression; d) Patients who have received any lung cancer immunotherapy after disease progression; e) Patients who have received anti-angiogenic drugs such as bevacizumab after disease progression; f) Patients who have received major surgery (including biopsy) or major trauma within 4 weeks before the first administration of the study drug; Patients who are expected to require major surgery during the study; g) Patients who have received more than 30% bone marrow irradiation or large-area radiotherapy within 4 weeks before the first administration of the study drug; i) Patients who have used strong CYP3A4 inhibitors, inducers, or drugs with narrow therapeutic windows that are sensitive substrates of CYP3A4 within 7 days before the first administration of the study drug.\n2. Patients with only local recurrence and who are suitable for radical chest radiotherapy and chemotherapy.\n3. Patients with any complications or other malignancies who require standard treatment or major surgery within 2 years after the first administration of study treatment.\n4. Severe cardiovascular and cerebrovascular diseases, including but not limited to cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction, unstable angina, heart failure ≥ grade II (New York Heart Association (NYHA) classification) within 6 months before enrollment, and severe arrhythmias (including: requiring drug control during the study; the drugs used will interfere with the normal treatment of the study drugs; arrhythmias that cannot be controlled by drugs).\n5. A history of interstitial lung disease, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.\n6. Non-healing wounds, active peptic ulcers, or fractures.\n7. Patients with other malignancies other than non-small cell lung cancer within 5 years before enrollment, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ.\n8. Patients with residual toxicity from previous treatment that was greater than CTCAE grade 1 and failed to be relieved at the start of study treatment, excluding those with alopecia and grade 2 neurotoxicity caused by previous chemotherapy.\n9. Spinal cord compression or brain metastasis, unless asymptomatic, stable, and without the need for steroid treatment for at least 2 weeks before the first dose of study treatment.\n10. Patients with any severe or poorly controlled systemic disease, such as active bleeding physique or active infection, as judged by the investigator. Chronic diseases do not need to be screened.\n11. Patients with refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow study drugs, or previous extensive intestinal resection may affect the adequate absorption of osimertinib.\n12. Meet any of the following cardiac examination results:\n\n    1. The average corrected QT interval (QTc) obtained from 3 electrocardiograms (ECG) at rest is \\> 470 msec, and the QT interval correction (QTcF) is performed using the Fridericia formula;\n    2. The resting ECG shows various clinically significant rhythm, conduction or ECG morphology abnormalities (such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block and PR interval \\> 250 msec);\n    3. The presence of any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death of a first-degree relative under 40 years old, or any concomitant medication that prolongs the QT interval;\n    4. Left ventricular ejection fraction (LVEF) ≤ 40%. 13. Insufficient bone marrow reserve or organ function, reaching the following laboratory limits:\n\n    a) Absolute neutrophil count 2.5 times the upper limit of normal (ULN); if there is liver metastasis, alanine aminotransferase\\> 5×ULN; e) If there is no clear liver metastasis, aspartate aminotransferase\\> 2.5×ULN; if there is liver metastasis, aspartate aminotransferase\\> 5×ULN; f) If there is no clear liver metastasis, total bilirubin\\> 1.5×ULN; or if Gilbert syndrome (unconjugated hyperbilirubinemia) or liver metastasis exists, total bilirubin\\> 3×ULN; g) Creatinine\\> 1.5×ULN and creatinine clearance 1.5×ULN only need to confirm creatinine clearance.\n\n14\\. Women who are breastfeeding or have a positive blood or urine pregnancy test within 3 days before the first dose of study treatment.\n\n15\\. Patients with proteinuria (urine test strip test) ≥2+ should undergo 24-hour urine collection. Patients are allowed to be enrolled if they show ≤1 g protein within 24 hours, and are not allowed to be enrolled if they show \\>1g.\n\n16\\. History of hypersensitivity to any active or inactive ingredient of osimertinib or to drugs with similar chemical structure to osimertinib or of the same class as osimertinib.\n\n17\\. Any severe or uncontrolled eye disease that may increase the patient's safety risk as determined by the doctor.\n\n18\\. Patients who may not comply with the study procedures and requirements as determined by the investigator.\n\n19\\. Patients who are determined by the investigator to have any condition that endangers patient safety or interferes with study assessments.","100 Years",{"count":210,"type":22},54,[25],"This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery. The main questions it aims to answer is: whether EGFR-TKI is effective in the re-treatment of NSCLC after postoperative adjuvant targeted therapy relapse.",[214,28],"Lung Neoplasms","NOT_YET_RECRUITING","2024-07-30",{"date":218,"type":33},"2024-07-31",{"date":220,"type":22},"2024-07",{"date":222,"type":22},"2028-05",{"name":224,"class":40},"Jin Ying",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100540677","phase-2-high-dose-furmonertinib-versus-osimertinib-in-advanced-egfrm-nsclc-patients-with-brain-metastases-100540677","NCT06319950","High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases","High-dose Furmonertinib Versus Osimertinib as First-line Treatment in Advanced EGFR Mutation-positive NSCLC Patients With Brain Metastases: a Multi-center, Randomized, Controlled, Prospective, Phase II Clinical Trial","Inclusion Criteria:\n\n* Male or female subjects aged \\>=18 and \\\u003C=80 years old.\n* Patients with histologically or cytologically confirmed NSCLC with adenocarcinoma or adenocarcinoma components predominant, and with central nervous system metastases (with measurable lesions).\n* The tissue or blood sample is determined to be EGFR positive (including rare EGFR mutations) by testing by a tertiary Class A hospital or a qualified testing institution, and the tissue submitted for testing cannot be from a tumor lesion that has been treated with radiation, but can be used for a new lesion after local treatment.\n* Patients who had not previously received systemic anti-tumor therapy for locally advanced or metastatic non-small cell lung cancer (patients who had received first-line chemotherapy but had not received TKIs could be enrolled). Patients who have undergone radical surgery, radical chemo-radiotherapy, or adjuvant therapy (chemotherapy, radiation) for early NSCLC may be enrolled if they later develop disease recurrence or metastasis.\n* Stable brain metastases that do not require local treatment of brain metastases either immediately or planned during the study period.\n* According to RECIST v1.1, enrolled patients should have at least one tumor lesion in all tumors that can meet the following requirements: they have not been treated with local therapy such as radiotherapy in the past, and can be accurately measured at baseline, and the longest diameter at baseline is ≥10mm (in the case of lymph nodes, the short diameter is ≥15mm). Lesions that have previously received local treatment (radiotherapy or other treatment) can only be measured if disease progression occurs more than 6 months after the end of treatment.\n* ECOG PS 0-1, and with no deterioration during the first 2 weeks of the study and expected survival time of no less than 3 months.\n* Patients should have sufficient bone marrow reserve function, and no liver, kidney, coagulation dysfunction, laboratory test values must meet the following conditions:\n\n  1. Absolute neutrophil count ≥ 1.5×109\u002FL, and white blood cell count ≥3×109\u002FL;\n  2. PLT ≥100×109\u002FL;\n  3. Hb ≥90g\u002FL;\n  4. Serum Cr ≤1.5×ULN and eGFR ≥50 mL\u002Fmin;\n  5. AST and ALT≤2.5×ULN (or AST and ALT≤5×ULN for patients with liver metastasis)\n  6. In the absence of proven liver metastasis, TB ≤1.5×ULN (or TB ≤3×ULN for patients with liver metastasis or Gilbert syndrome;\n  7. INR ≤1.5, and APTT ≤1.5×ULN.\n* Male patients and female patients of reproductive age should take adequate contraceptive measures within 3 months after signing the study informed consent to the last study drug treatment; In women of childbearing age, pregnancy test results are negative within 7 days before the first dose.\n* All previous treatment-related toxicities (except alopecia and grade 2 neurotoxicity associated with previous platinum chemotherapy) had been recovered (to ≤ grade 1) before first administration of the investigational drug.\n* The subject is able to understand and voluntarily sign a written informed consent (which must be signed prior to performing any procedure specified in the study protocol).\n* Be able to voluntarily complete the study procedures and follow-up examinations as required by the study protocol.\n\nExclusion Criteria:\n\n* Patients with the following treatments:\n\n  1. Previous use of any EGFR TKIs therapy;\n  2. Previously received systemic antitumor therapy (such as targeted therapy, biotherapy, immunotherapy, etc.) for advanced\u002Fmetastatic non-small cell lung cancer;\n  3. Standard chemotherapy within 28 days before the first administration of the study drug; The study received anti-tumor therapy with traditional Chinese medicine within 7 days before the first administration of the drug;\n  4. Previous WBRT; Had received \\>30% of bone marrow radiotherapy or extensive radiotherapy within 28 days prior to the first dose of the study drug; Local radiotherapy (e.g., thoracic and rib radiotherapy) or palliative radiotherapy for bone metastases within 7 days prior to initial administration of the study drug;\n  5. Uncontrolled pleuroperitoneal effusion and pericardial effusion;\n  6. Uncontrollable cancerous pain; Anesthetic painkillers did not reach a stable dose at the time of enrollment;\n  7. Study major surgery within 28 days before the first administration of the drug ( major surgery refers to grade 3 and grade 4 surgery in Measures for the Clinical Application of Medical Technology in China, on May 1, 2009 );\n  8. Has received a strong inducer or suppressor of CYP3A4 within 14 days prior to initial administration of the investigatory drug or requires continued treatment during the study period (including Chinese herbal medicine, see Appendix for a list of drugs);\n  9. Patients who are receiving and require continued treatment during the study with drugs known to prolong the QTc interval or that may cause tip torsion ventricular tachycardia (see Appendix for a list of drugs);\n  10. Participants who have participated in other clinical trials within 28 days prior to the first administration of the investigational drug (except non-interventional drug trials);\n* Patients with primary malignant brain tumors and unstable brain metastases. Definition of unstable brain metastases: Patients with CNS complications who require emergency neurosurgical treatment (such as surgery); Patients with an equivalent dose of dexamethasone or more than 5mg of glucocorticoids, mannitol or diuretics to control symptoms of brain metastases should be administered within 14 days prior to the first dose; The first study looked at patients who had received local radiotherapy or gamma knife treatment within 14 days prior to administration. Patients with meningeal metastasis were excluded.\n* Patients who have had or have a history of other malignancies within the past 5 years (except cured basal cell or squamous cell carcinoma of the skin, papillary carcinoma of the thyroid gland, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast).\n* The patient had symptoms of spinal cord compression caused by the tumor.\n* Clinically significant gastrointestinal dysfunction that may affect the intake, transport, or absorption of investigational drugs, such as inability to take oral drugs, difficult to control nausea or vomiting, a history of extensive gastrointestinal resection, Untreated recurrent diarrhea, atrophic gastritis (onset age less than 60 years), untreated stomach disease requiring long-term use of PPI acid suppressants, Crohn's disease, ulcerative colitis.\n* Cardiovascular and cerebrovascular diseases\u002Fsymptoms\u002Findications that meet any of the following conditions:\n\n  1. Average resting QTc≥470ms (corrected QT interval, calculated according to Fridericia's formula, see Appendix 18-9), the average QTc of 3 ECG intervals of more than 5 minutes, and the QT interval should be measured from the beginning of the QRS complex wave to the end of the T wave;\n  2. Any abnormalities in rhythm, conduction, or morphology of the clinically significant resting ECG, such as complete left bundle branch block, 2nd and 3rd degree heart block, PR interval \\> 250ms;\n  3. Any factors that increase the risk of prolonged QTc or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or sudden unexplained death in a first-degree relative under the age of 40-year-old, or any combination of medications known to prolong the QT interval;\n  4. LVEF \\\u003C50%;\n  5. Patients with a history of decreased myocardial contractility and related symptoms in the 6 months prior to study administration, such as chronic congestive heart failure, pulmonary edema, or decreased ejection fraction;\n  6. Patients with a history of acute and chronic cardiovascular and cerebrovascular disease and related symptoms within 6 months prior to study administration, such as myocardial infarction, severe or unstable angina pectoris, cerebral infarction, cerebral hemorrhage, or transient ischemic attack.\n* Persons infected with HIV, syphilis, HCV or HBV, meeting the following conditions:\n\n  1. HBs Ag positive and HBV DNA ≥2000cps\u002F mL (or 500IU\u002F mL);\n  2. Anti-HCV antibody and HCV RNA positive;\n  3. HIV antibody positive.\n* Prior or screening history of interstitial lung disease or ILD, or drug-induced ILD, or radiation pneumonia requiring hormone therapy, or any evidence of active ILD (such as acute onset or progressive pneumonia\u002Fpulmonary fibrosis at baseline), or pulmonary symptoms deemed unsuitable for inclusion by the investigator or risk factors deemed unsuitable for interstitial lung disease.\n* Had previously received allogeneic bone marrow transplantation.\n* Pregnant and lactating women.\n* The patient has any other disease or medical condition that is unstable or may affect their safety or study compliance, any serious or uncontrolled systemic disease, including autoimmune disease requiring corticosteroid therapy, uncontrolled hypertension (SBP ≥150 mmHg or DBP ≥95 mmHg), Uncontrolled diabetes, active bleeding, eye lesions, and other serious mental, neurological, cardiovascular, or respiratory diseases.\n* Known or suspected allergy to the investigational drug ingredient or its analogues.\n* The subjects were judged by the investigator to be unfit for this study.","80 Years",{"count":234,"type":22},255,[25],"The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.",[28],[239,240,241,242],"non-small cell lung cancer (NSCLC)","brain metastases","epidermal growth factor receptor (EGFR)","tyrosine kinase inhibitors (TKI)","2024-03-13",{"date":245,"type":33},"2024-03-20",{"date":247,"type":22},"2024-04-01",{"date":249,"type":22},"2026-12-30",{"name":251,"class":40},"Taizhou Hospital",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":275},"100445791","phase-3-a-randomised-open-label-phase-iii-trial-of-reduced-frequency-pembrolizumab-immunotherapy-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-nsclc-100445791","NCT05085028","A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design","REFINE-Lung","Inclusion Criteria:\n\n* Written informed consent prior to initiation of any study procedures and willingness and ability to comply with the study schedule\n* Any patient ≥18yrs who has received 6 months of pembrolizumab treatment with or without chemotherapy for advanced Non small cell lung cancer who is planned to continue immunotherapy treatment because of continued benefit.\n\nExclusion Criteria:\n\n* Disease progression or not tolerating treatment at 6 months into therapy\n* Clinician does not intend to continue immunotherapy\n* Any patient with a synchronous primary cancer. This includes any new cancer diagnoses or relapse of previously treated cancer since starting pembrolizumab treatment.\n* Any patient currently receiving an investigational agent and\u002For using an investigational device or has participated in a study of an investigational agent and\u002For used an investigational device within 28 days of randomisation.",{"count":261,"type":22},1750,[263],"PHASE3","REFINE-lung will test whether reduced pembrolizumab dose frequency after 6 months of standard treatment is safe and effective. Patients treated with 1st line pembrolizumab who are progression free and otherwise planning to continue therapy at 6 months will be initially randomised to control 6 weekly versus interventional 12 weekly therapy. If an interim analysis shows that the 12 weekly treatment is no less effective, subsequent patients will also be randomised to 9, 15 and 18 weekly treatment frequency arms. Patients who progress on a reduced frequency arm will be offered re-escalation to standard 6 weekly therapy.",[28],"2024-03-06",{"date":268,"type":33},"2024-03-07",{"date":270,"type":33},"2022-06-23",{"date":272,"type":22},"2027-05-31",{"name":274,"class":40},"Imperial College London",37,{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":284,"conditions":285,"keywords":289,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100480587","i3lung-integrative-science-intelligent-data-platform-for-individualized-lung-cancer-care-with-immunotherapy-100480587","NCT05537922","I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C\u002F= 2.\n* Histologically confirmed diagnosis of stage IIIB\u002FC-IV Non-Small-Cell Lung Cancer\n* Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort.\n* Patients with CNS metastasis are allowed\n* Patients with driver genomic alterations are allowed (only for retrospective cohort)\n* Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort)\n* Availability of at least one FFPE block for -omics data generation (only for prospective cohort)\n\nExclusion Criteria:\n\n* Patients without minimal treatment information data to be included in the retrospective cohort\n* Prior treatment for advanced disease (only for prospective cohort)\n* Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires",{"count":283,"type":22},2200,"I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase.\n\nThe retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs.\n\nThe prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.",[286,287,28,288],"Non Small Cell Lung Cancer","Lung Cancer Metastatic","Lung Adenocarcinoma",[290,291,292],"NSCLC","Artificial Intelligence","Immunotherapy","2023-01-05",{"date":295,"type":33},"2023-01-06",{"date":297,"type":33},"2022-10-01",{"date":299,"type":22},"2027-10-01",{"name":301,"class":40},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",4]